Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14517867 | 0.88 | ADORA2B (0.79) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14293825 | 0.88 | ADORA2B (0.81) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1222451 | 0.87 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1780810 | 0.87 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1781047 | 0.86 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1779300 | 0.86 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL4758458 | 0.80 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14517874 | 0.77 | ADORA2B (0.82) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1779353 | 0.76 | ADORA2B (0.80) | ADORA2BADORA1ADORA2A | |
| SCHEMBL5330781 | 0.74 | ADORA2B (0.76) | ADORA2BADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC | 2011-05-19 | — | — | US | claimed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-06-29 | — | — | US | claimed |
| US-20260124327-A1 | Compounds Targeting Carbonic Anhydrase IX and Uses Thereof | RAYZEBIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12600742-B2 | Markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy | WWIKY BIOSCIENCES INC. (CA) | 2026-04-14 | — | — | US | disclosed |
| EP-4719497-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | Rayzebio, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12583887-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12559521-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| US-20250277211-A1 | LPA inhibitors and uses thereof | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| EP-4610356-A1 | RNA INHIBITOR FOR INHIBITING LPA GENE EXPRESSION AND USE THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| US-20220301733-A1 | Nuclear Material and Methods | FUSION ENERGY SOLUTIONS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-11446383-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20220249710-A1 | BIOREDUCTIVELY-ACTIVATED COMPOUNDS, THEIR PRODRUGS, RADIOPHARMACEUTICALS, THE COMPOSITIONS, AND THEIR APPLICATIONS IN MULTIMODAL THERANOSTIC MANAGEMENT OF HYPOXIA DISEASES INCLUDING CANCER | WWIKY BIOSCIENCES INC. (CA) | 2022-08-11 | — | — | US | disclosed |
| US-11384106-B2 | Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers | EMORY UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| CN-114703184-A | LPA inhibitor and use thereof | 厦门甘宝利生物医药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114695973-A | Preparation method of low-temperature zinc ion battery | 电子科技大学 | 2022-07-01 | — | — | CN | disclosed |
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC | 2011-05-19 | — | — | US | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | ADORA2B 1117/4885ADORA1 464/4885ADORA2A 1330/4885 |
| US-11446383-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | ADORA2B 3274/4885ADORA1 2210/4885ADORA2A 2686/4885 |
| US-12559521-B2 | PSMA imaging agents | KLK3, PSMA1, PSMA6 | ADORA2B 3038/4885ADORA1 1313/4885ADORA2A 2713/4885 |
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA1 4/4885ADORA2A 2/4885 |
| US-12583887-B2 | PSMA imaging agents | KLK3, PSMA3, PSMA1 | ADORA2B 2703/4885ADORA1 1697/4885ADORA2A 2440/4885 |
| US-20220249710-A1 | BIOREDUCTIVELY-ACTIVATED COMPOUNDS, THEIR PRODRUGS, RADIOPHARMACEUTICALS, THE COMPOSITIONS, AND THEIR APPLICATIONS IN MULTIMODAL THERANOSTIC MANAGEMENT OF HYPOXIA DISEASES INCLUDING CANCER | HIF1A, HIF1AN, PAICS | ADORA2B 308/4885ADORA1 191/4885ADORA2A 60/4885 |
| US-12600742-B2 | Markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy | HIF1A, HIF1AN, HYOU1 | ADORA2B 868/4885ADORA1 1148/4885ADORA2A 698/4885 |
| US-20260124327-A1 | Compounds Targeting Carbonic Anhydrase IX and Uses Thereof | CA9, CA13, CA4 | ADORA2B 1016/4885ADORA1 1527/4885ADORA2A 2718/4885 |
| US-11384106-B2 | Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers | SLC16A8, S100A8, FGF23 | ADORA2B 1232/4885ADORA1 542/4885ADORA2A 352/4885 |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.